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Abstract
Binge alcohol (ethanol) drinking is a destructive pattern of ethanol consumption that may
precipitate ethanol dependence, a chronic, debilitating, and prevalent health problem. While an
abundance of research has focused on the neurochemical underpinnings of ethanol dependence,
relatively little is known about the mechanisms underlying the heavy consumption characteristic
of binge ethanol drinking. Recently, a simple preclinical model termed “drinking in the dark”
(DID) was developed to examine binge-like ethanol consumption in a rodent population. This
assay capitalizes on the predisposition of C57BL/6J mice to voluntarily consume substantial
quantities of a high concentration (20% v/v) ethanol solution, resulting in pharmacologically
relevant blood ethanol concentrations (BECs). This review provides a comprehensive overview of
recent literature utilizing this model to investigate the neuromodulatory systems that may
influence binge ethanol drinking. Studies examining the glutamatergic and opioidergic systems
not only provide evidence for these systems in the modulation of binge-like ethanol consumption,
but also suggest this preclinical model has predictive validity and may be an appropriate tool for
screening novel pharmacological compounds aimed at treating binge ethanol drinking in the
human population. Additionally, this review presents evidence for the involvement of the
GABAergic, dopaminergic, nicotinic, and endocannabinoid systems in modulating binge-like
ethanol consumption. Finally, recent evidence shows that corticotropin-releasing factor (CRF),
agouti-related protein (AgRP), neuropeptide Y (NPY), and ghrelin are also implicated as
impacting this pattern of ethanol consumption.
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1. Introduction
Alcohol (ethanol) dependence is a debilitating and costly health problem affecting many
Americans and their families each year, and is one of the top preventable causes of death in
the world [1, 2]. As such, the neurochemical pathways underlying this disorder are currently
the subject of intense investigation. Traditionally, preclinical research into the molecular
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underpinnings of alcoholism has utilized models of chronic ethanol drinking; to date, far less
attention has been focused on binge ethanol drinking, a pattern of behavior that may emerge
prior to, and contribute to the development of, ethanol dependence.
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) defines an ethanol
‘binge’ as a pattern of drinking that produces blood ethanol concentrations (BECs) greater
than 0.08% (80 mg/dl) [3]. Typically, the pattern of drinking required to produce a BEC of
this level is about 5 and 4 drinks in a 2-hour period for the average adult male and female,
respectively. Although popular media generally associates this pattern of drinking with a
younger demographic, most notably young college students, binge ethanol consumption is
also prevalent among the adult population [4]. Indeed, a majority of binge drinking episodes
in the United States involve adults over the age of 26 [5]. A substantial literature has
associated binge ethanol drinking with both negative short- and long-term health and social
consequences. For example, binge drinking has been linked with not only a decrease in
general health, but also a number of specific health risks, including hypertension and type 2
diabetes [6, 7]. Additionally, binge ethanol drinking has been linked with an increased
proclivity to partake in risky behaviors, including unprotected sex and impaired driving [5,
8, 9]. Finally, recent studies have also indicated that binge ethanol drinking early in life is
positively associated with an increased risk of developing ethanol dependence later in life
[8, 10, 11]. By studying the neurobiological mechanisms that underlie binge ethanol
drinking, it may be possible to understand, and thus develop pharmacological treatments
aimed at preventing, the neuroplastic alterations that develop during the transition to an
ethanol-dependent state.
2. Binge Drinking: Preclinical Models
Due to inherent species differences, it is unlikely that a single rodent model can be
developed to fully characterize ethanol abuse disorders and dependence, multi-faceted and
complex disorders with diverse physical and social consequences [2]. Thus much of the
current work in the field relies on partial models to closely examine specific facets of these
disorders. For example, two-bottle choice methods have been successfully used to examine
ethanol preference, while self-administration and relapse models have been used to
investigate mechanisms contributing to the motivation to seek and consume ethanol [12].
Indeed, while these and other protocols have proven extremely valuable in examining
certain features of ethanol dependence, none of these models accurately address the defining
characteristics of binge ethanol drinking. Additionally, many of these methods (most
notably, self-administration models) require extensive training, the use of food and/or water
deprivation, or sucrose fading techniques to elicit ethanol consumption. Finally, rodents in
these models often do not consume enough ethanol (or enough ethanol over a short enough
period of time) to generate behavioral and/or pharmacological intoxication [12]..
While no mouse model can perfectly model a human disorder, a rodent model of binge-like
ethanol drinking should fulfill certain criteria in order to reliably translate to humans.
Briefly, the animal should voluntarily and orally self-administer ethanol to a substantial
degree and over a limited time frame, such that it generates a pharmacologically relevant
BEC analogous to that specified by the NIAAA [3]. Additionally, the animal should
consume the ethanol for post-ingestive intoxicating effects, and not simply for taste or
caloric fulfillment. Binge drinking has been proposed as a pattern of behavior that may lead
to, or be involved in the transition to, dependence; thus a model of binge drinking need not
meet all of the requirements of a broader model of ethanol dependence, such as the
expression of tolerance or the presentation of withdrawal symptoms [13–15].
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Several currently utilized models fulfill some, but not all, of the criteria for a model of
binge-like ethanol drinking. For example, repeated intragastric delivery of a high dose of
ethanol (e.g., 5g/kg) has been a widely-used and validated as a technique that results in
pharmacological and behavioral intoxication [16]. In a recent study, this technique was used
to examine alterations in adult cholinergic genes following adolescent intragastric delivery
of ethanol sufficient to achieve staggeringly high BECs (nearly 300mg/dl) [17]. This
intragastric method of inducing high ethanol exposure in rodents is valuable in many ways,
including the ability to both precisely control the amount of ethanol administered as well as
ensure all animals achieve a pharmacologically relevant BEC. Intragastric methods of
ethanol delivery are thus well suited for studies in which the focus is the neurobiological
response to a high dose of orally administered ethanol; however, this method is perhaps not
the most appropriate for modeling voluntary human ethanol consumption.
The scheduled high alcohol consumption (SHAC) protocol is another useful procedure that
has been repeatedly shown to elicit high levels of ethanol drinking (and corresponding high
BECs, often reaching over 100mg/dl) [18]. Indeed, this procedure has yielded an abundance
of information regarding the role of opioidergic, glutamatergic, and GABAergic systems in
high ethanol consumption [19–21]. However, despite the reliable high amounts of ethanol
consumption garnered with this model, the SHAC procedure relies heavily on fluid
restriction, often restricting fluid access for the majority of the day: in some cases, total fluid
access is restricted to just 90-min per day. Thus, while this procedure yields high levels of
ethanol consumption, it relies on an unnatural and stressful manipulation to do so. These
aforementioned techniques, as well as others beyond the scope of this review, induce high
levels of ethanol consumption but are similar in that they rely upon elaborate and artificial
means of garnering high BECs – for example, bypassing the animal’s choice to consume via
intragastric delivery, or severely restricting total fluid access. Several recent studies have
also taken advantage of an adapted intermittent access two-bottle choice procedure whereby
both rats [22] and mice [23] voluntarily consume large amounts of 20% ethanol (and
achieve pharmacologically relevant BECs). Under this procedure, animals are given 24 h
access to a 20% ethanol solution every other day, typically three sessions per week. Mice
undergoing this procedure show signs of ethanol withdrawal (as measured by handling
induced convulsions [23]. Further, both Naltrexone and acamprosate significantly reduced
20% ethanol consumption in rats under this intermittent access protocol [22]. This
procedure, while a reliable method of inducing excessive drinking leading to dependence-
like behaviors, utilizes long periods of ethanol deprivation and extended periods of ethanol
consumption; as the NIAAA definition of a binge typically translates to 4–5 drinks in a two-
hour period for the average adult [3], this extended access may not be the most appropriate
method for modeling binge-like ethanol consumption.
3. Drinking in the Dark (DID)
In the past several years, a simple mouse model termed “drinking in the dark” has gained
acceptance as a robust model of binge-like ethanol drinking that consistently results in both
pharmacologically relevant BECs and signs of behavioral intoxication [24, 25]. This
protocol has a number of inherent advantages over other models of binge ethanol drinking.
First, DID capitalizes on the natural nocturnal ingestive behavior of mice, negating the need
for any kind of fluid restriction to induce drinking [26]. Thus, presentation of an ethanol-
containing solution during the early phase of the dark cycle (when mice are most active) to a
strain of mice (typically C57BL/6J) genetically predisposed to voluntarily consume ethanol,
reliably generates BECs of greater than 80mg/dl (and typically, greater than 100mg/dl),
thereby exceeding the guidelines as set by the NIAAA [3]. Although the motivation for the
C57BL/6J mice to consume high amounts of ethanol under the DID protocol is unclear,
mice achieving BECs of greater than 100mg/dl have been shown to demonstrate behavioral
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signs of intoxication as demonstrated on both the balance beam and accelerating rotarod
[25]. Additionally, High Drinking in the Dark (HDID) mice (generated by the intercrossing
of 8 inbred strains, including C57BL/6J), have been selectively bred to achieve high BECs
following binge-like ethanol consumption of a 20% ethanol solution [27, 28]. These mice
will no doubt prove extremely useful in examining the neurobiological correlates of binge-
like ethanol consumption.
Although the majority of this review focuses on DID as a mouse model of binge-like ethanol
drinking, a modified DID protocol has also been successfully used to model binge-like
ethanol drinking in rats (see section 5 below). One potential caveat to the DID protocol is
that it relies heavily on the well-established predisposition of C57BL/6J mice to more
readily consume ethanol than other, low-ethanol-drinking strains (such as the DBA/2J), thus
potentially reducing the ability of this protocol to fully model the genetic diversity seen in
ethanol drinkers. However, this characteristic may make DID particularly useful in modeling
binge-like ethanol consumption in individuals with a similar genetic predisposition to heavy
ethanol consumption (and potentially a predisposition to the development of ethanol
dependence). Additionally, as noted by Rhodes et al. (2007) and observed elsewhere, there
is a great deal of variation within this high-drinking strain in regards to the amount of
ethanol consumed and the BECs achieved, potentially suggesting an epigenetic influence on
the high amount of ethanol consumed with this protocol [25, 29].
In the typical DID procedure, the homecage water bottle of individually housed C57BL/6J
mice is replaced with a bottle containing 20% (v/v) ethanol for 2-h, 3-h after the beginning
of the dark cycle, for 3 days. On the fourth day, the same procedure is followed, except that
the ethanol-containing bottle is left on the cage for 4-h [24]. It is important to note that with
this procedure, mice will voluntarily consume a relatively high concentration (typically
20%, v/v) of ethanol without requiring any training or prior exposure, and that this
procedure does not require fluid restriction or a sucrose fading procedure [24]. In fact, while
the water bottle is commonly removed during the 2-h to 4-h procedure, Rhodes et al. (2007)
showed that mice drank similar amounts of ethanol with or without water available,
although mice with concomitant access to water achieved BECs approximately 40% lower
than those without simultaneous water access [25]. As the mice drink similar amounts of
ethanol regardless of the presence of water, this suggests that thirst is not a motivating factor
in generating high ethanol intake; additionally, the lower BECs achieved by mice with
access to both ethanol and water may be explained by the dilution of the ethanol in both the
stomach and blood by the water [25].Importantly, research from our laboratory has
demonstrated that the excessive drinking established with the DID procedure does not result
from fulfilling a caloric need, as administration of neither the orexigenic peptide ghrelin nor
the anorectic protein leptin significantly altered ethanol consumption using this procedure,
nor did food restriction alter the level of binge-like drinking [30]. These findings suggest
that the high level of ethanol consumption is likely due to other, post-ingestive, effects.
In addition to being a simple technique that can serve as a high-throughput screening
mechanism, the DID procedure is advantageous because its basic tenets are easily adaptable
to accommodate various experimental demands. For example, the number of days in a single
DID cycle can be extended in order to allow sufficient habituation to handling and other
procedures related to delivery of a drug of interest [31]. Likewise, the duration of a single
cycle can be shortened in order to meet experimental restrictions, as long as certain basic
guidelines (i.e., limited access beginning 3-hr into the dark cycle) are held constant [32].
Further, as each ‘cycle’ of binge-like ethanol drinking is typically only four days long,
examining the effect of repeated cycles of binge-like ethanol consumption is quite practical.
Finally, the DID procedure lends itself well to examining the specificity of effects of
pharmacological compounds on binge-like ethanol drinking, as concurrent water, sucrose,
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and other controls are simple to perform. Together, this flexible methodology, combined
with the strength and consistency of drinking behavior and BECs achieved, make DID an
extremely beneficial and powerful research tool for examining a rodent correlate of human
ethanol binge drinking.
4. DID with C57BL/6J Mice: The Neurobiology of Binge-Like Ethanol
Drinking
The DID model has been influential in examining both the behavioral aspects as well as the
neurobiological underpinnings of binge-like ethanol consumption. As such, DID has been
widely used to investigate the role of neuromodulatory systems that may impact this pattern
of consumption. See Table 1 for a summary of the results that are reviewed below.
4.1 Glutamatergic system
A substantial literature has confirmed an integral role of the glutamatergic system in ethanol
dependence: acamprosate, which is thought to act as a functional glutamate antagonist, is
one of a select few drugs accepted for pharmacological treatment of ethanol dependence
[33]. Indeed, a meta-analysis of 13 clinical trials confirmed the efficacy of acamprosate as a
therapeutic approach for maintaining abstinence [34]. In a recent preclinical study,
intraperitoneal (i.p.) administration of both acamprosate and 6-Methyl-2-(phenylethynyl)
pyridine (MPEP; a metabotropic glutamate 5 receptor (mGLuR5) antagonist) dose-
dependently reduced binge-like ethanol consumption using the 2-h (acamprosate) or 4-h
(MPEP) DID procedure [35]. While select doses of acamprosate were able to selectively
decrease ethanol intake by approximately 20%, MPEP was more potent and had a longer
duration of action [35]. Together, these data not only suggest a role for mGluR signaling in
modulating excessive (binge) ethanol intake, but also suggest that the DID protocol has
predictive validity. Thus DID may be an appropriate tool for screening novel
pharmacological compounds aimed at treating binge ethanol consumption.
4.2 GABAergic system
The DID procedure has also been valuable in exploring the role of the GABAergic system in
binge-like ethanol drinking. In a modified 7-d DID procedure, both systemic and posterior
ventral tegmental area (VTA) administration (but not anterior VTA administration) of the
imidazobenzodiazepine derivative Ro15-4513, a benzodiazepine partial inverse agonist,
dose-dependently reduced 20% ethanol consumption (and related BECs), whereas
consumption of a 5% sucrose solution was not affected [36]. Likewise, in a modified 5-d
DID procedure, systemic baclofen (a GABAB agonist) dose dependently increased, while
systemic muscimol (a potent GABAA agonist) decreased ethanol intake without affecting
water consumption [37]. A separate study localized the effect of baclofen to the anterior
VTA [38]. Together, these data suggest involvement of the GABAergic system of the VTA
in modulating binge-like ethanol consumption.
4.3 Dopaminergic and opioidergic systems
Both dopaminergic and opioidergic neurotransmitter systems have long been established as
having integral involvement in drug and ethanol dependence [39, 40]. A recent critical study
examined the involvement of these systems in the excessive ethanol consumption
characteristic of binge ethanol consumption using the DID procedure. Naltrexone (a
nonspecific competitive opioid receptor antagonist) and GBR 12909 (a dopamine reuptake
blocker) dose-dependently reduced ethanol consumption in a modified 2-d DID procedure
[41]. While the doses of Naltrexone that reduced ethanol consumption had no effect on
water or sugar water consumption, GBR 12909 also reduced sugar water consumption. More
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recently, mice lacking the long version of the dopamine 2 receptor (D2R) drank more 20%
ethanol than their wild-type counterparts in a DID procedure, suggesting a role for specific
dopamine receptors in excessive ethanol intake [42]. Together these results further implicate
both the opioidergic and dopaminergic systems in modulating excessive ethanol
consumption, such as that seen in binge ethanol drinking. Additionally, these results further
confirm the predictive validity of the DID model, as Naltrexone, known to reduce ethanol
consumption in human alcoholics, also reduced ethanol binge-like ethanol consumption in
C57BL/6J mice.
4.4 Nicotinic system
The comorbidity of nicotine and ethanol abuse has been well documented, yet much about
this complex relationship remains unclear [43, 44]. Neuronal nicotinic acetylcholine
receptors (nAChRs) have been found to partially mediate the reinforcing properties of
ethanol, and the nicotinic receptor partial agonist varenicline has been found to selectively
reduce ethanol seeking and consumption in rodent models [45, 46]. Recent studies have also
implicated nAChRs in binge ethanol consumption using modified (2-d) versions of the DID
procedure. In the first study, systemic mecamylamine hydrochloride (mecamylamine; a
nonspecific and noncompetitive nAChR antagonist) reduced 20% ethanol consumption and
related BECs relative to saline-treated control mice [47]. This effect was specific to ethanol,
as mecamylamine did not affect sucrose consumption, and supports previous data showing
that mecamylamine, when injected into the VTA, reduces ethanol consumption in high-
drinking Wistar rats [48]. Interestingly, systemic treatment with nicotinic agonists cytisine
and nicotine also reduced binge-like ethanol consumption, an effect possibly attributable to
the enormity and complexity of the nAChR subunit system [47]. Finally, subcutaneous
administration of the nicotinic alkaloid lobeline, which acts as a mixed agonist-antagonist at
nAChRs, also reduced 20% ethanol consumption in a 2-d DID procedure without
significantly affecting sucrose or water consumption [32]. These results suggest that the
relationship between nicotine and ethanol use may begin early in, or prior to, the
development of ethanol dependence.
4.5 Endocannabinoid system
An abundance of both preclinical and clinical literature has suggested both direct and
indirect roles of the endocannabinoid system in ethanol dependence (for a detailed review,
see [49]). Recent evidence has also implicated the cannabinoid receptor system in
modulating binge-like ethanol consumption by C57BL/6J mice. Systemic injection of the
synthetic cannabinoid agonist WIN 55-313 dose-dependently modulated ethanol
consumption of C57BL/6J mice in a modified (7-d) DID protocol [31]. While a low dose of
WIN 55-313 significantly increased initial ethanol consumption, higher doses significantly
decreased consumption, an effect likely due to nonspecific locomotor effects of a high dose
of the drug. However, bilateral infusion of the compound into the posterior VTA also altered
the time course of ethanol consumption throughout the binge session. Together, these results
suggest that the endocannabinoid system may not only be involved during ethanol
dependence, but also during binge ethanol drinking prior to the development of dependence.
4.6 Corticotropin-releasing factor (CRF)
A wealth of literature has implicated a role for the CRF system in ethanol’s effects following
both acute ethanol exposure as well as during procedures designed to model ethanol
dependence [39, 50, 51]. Work from our laboratory and others has expanded this literature to
show that the CRF system also plays an integral role in modulating binge-like ethanol
consumption. First, systemic administration of butyl-[2,5-dimethyl-7-(2,4,6-
trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-ethylamine (CP-154, 526), a potent and
selective agonist of the CRF type-1 receptor (CRF1R), attenuated binge-like ethanol
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consumption in C57BL/6J mice using the 4-d DID procedure [52]. The importance of CRFR
signaling in binge-like ethanol consumption was further confirmed as
intracerebroventricular (i.c.v.) infusion of α-helical CRF9–41, a nonselective CRFR
antagonist, attenuated and a CRF type-2 receptor (CRF2R) agonist Urocortin-3 (Ucn3)
blunted binge-like ethanol consumption [53]. Importantly, CRF1R antagonism did not alter
non-binge-like ethanol consumption using a modified DID protocol. When ethanol was
presented for 4-h, 3-h into the dark cycle for four consecutive days, mice achieved BECs of
under 40mg/dl; CRF1R antagonism did not significantly alter the moderate level of ethanol
consumption using this modified protocol, suggesting the CRF system plays an important
role specifically in the excessive ethanol intake seen with binge-like ethanol consumption
[52].
Further confirming involvement of the CRF system in modulating excessive ethanol intake,
microinjection of the CRF agonist Urocortin 1 (Ucn1) into the lateral septum in a slightly
modified DID procedure significantly decreased ethanol consumption [54]. Finally, more
recent work used the DID procedure to assess binge-like ethanol drinking in mutant mice
lacking normal production of either CRF, CRF1R, CRF2R, or Ucn1 [55]. Here again, the
CRF1R was affirmed as playing a critical role in modulating excessive ethanol consumption.
Together, the current research strongly suggests that the CRF system is involved in high (but
not low or moderate) ethanol consumption, which may in turn contribute to the development
of ethanol dependence.
4.7 Melanocortin (MC) Peptides
As previous literature has indicated an involvement of the MC receptor (MCR) system in
modulating neurobiological responses to ethanol and ethanol intake [56, 57], our laboratory
investigated the role of agouti-related protein (AgRP), an endogenous MCR antagonist, in
binge-like ethanol consumption using the standard 4-d DID procedure. [58]. In this study,
mutant mice lacking normal production of AgRP showed blunted binge-like ethanol
consumption (and a related decrease in BEC) relative to wild-type littermates [58]. Current
work is underway to assess the role of other MC-related peptides (e.g., α-MSH) in the
modulation of binge-like ethanol consumption.
4.9 Neuropeptide Y (NPY)
Recent work from our laboratory has provided evidence for a role of NPY signaling in
modulating binge-like ethanol drinking in C57BL/6J mice using the 4-d DID procedure
previously described [29]. First, i.c.v. infusion of NPY, an NPY Y1 (Y1R) receptor agonist,
and a Y2R antagonist significantly blunted binge-like ethanol consumption.
Immunohistochemical and electrophysiological approaches further implicated NPY
signaling in modulating this excessive ethanol consumption, as a history of binge-like
drinking significantly altered NPY, Y1R, and Y2R immunoreactivity in the central nucleus
of the amygdala (CeA), and increased NPY-induced inhibition of GABAergic transmission
in slice preparations of the CeA [29]. Interestingly, similar doses of centrally administered
NPY have previously been ineffective at altering low-level, non-binge-like ethanol
consumption (using a 2 hr voluntary consumption protocol) [59]. Taken together, these
results strongly suggest a role for NPY signaling in specifically modulating the excessive
consumption characteristic of binge ethanol drinking, potentially contributing to the
development of ethanol dependence.
4.8 Ghrelin
As previously indicated, systemic administration of the orexigenic peptide ghrelin did not
significantly alter 20% ethanol consumption using the DID procedure [30]. However, in a
modified 7-d DID procedure, systemic injection of the ghrelin receptor antagonist, D-Lys3-
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GHRP-6 not only caused a significant decrease in 20% ethanol consumption, but also
decreased ethanol preference in a modified 2-bottle DID procedure [60]. Together, these
results suggest that future work is needed to clarify the role ghrelin may play in excessive
ethanol intake, especially considering the important role this hormone is suggested to play in
obesity and other eating disorders [61].
5. DID with Rats: The Neurobiology of Binge-Like Ethanol Drinking
Although many investigations into the neurobiological underpinning of binge ethanol
consumption rely on a variation of a standard DID procedure using C57BL/6J mice [24],
several recent studies have taken advantage of ethanol-preferring rat strains using a similar
protocol termed drinking-in-the-dark-multiple-schedule-access (DID-MSA) [15, 62, 63]. In
this procedure, ethanol-preferring P-rats (which, like C57BL/6J mice, will voluntarily
consume a high-concentration ethanol solution) have concurrent access to water, 15%, and
30% ethanol: while water is available ad libitum, ethanol is available for three 1-h sessions
during the dark cycle, with each session separated by 2-h periods of ethanol abstinence [15,
64]. Interestingly, unlike the standard mouse DID protocol in which ethanol is presented 3-h
into the dark cycle, the maximum ethanol consumption using the DID-MSA procedure
occurs when ethanol is first presented immediately after lights out [63].
This DID-MSA procedure has been useful in examining how continuous ethanol exposure
and binge-like ethanol exposure differentially affect the expression of proteins involved in a
multitude of intracellular functions within brain reward neurocircuitry [65]. Additionally, a
more recent study examined changes in gene expression in regions of the extended
amygdala following binge-like ethanol exposure: results indicated that binge- like ethanol
drinking produces region-dependent alterations in gene expression within the nucleus
accumbens shell and the central nucleus of the amygdala, two areas previously implicated in
mediating the neurobiological effects of ethanol [62]. A modified DID-MSA protocol using
Sprague-Dawley rats (using temporary water restriction to enhance ethanol consumption),
has also been combined with self-administration procedures to examine how the P2rx4 gene,
which codes for a receptor in the purinergic system of ligand-gated ion channels, influences
the behavioral effects of ethanol [66]. Purinergic type 2 receptors have previously been
revealed as important targets for ethanol action and have been suggested to be important
mediators of ethanol-induced effects [67, 68]. Though the standard mouse DID procedure is
currently much more common than the rat DID-MSA model, DID-MSA holds great
potential for future studies; specifically, this rat DID model may prove exceptionally useful
when combined with self-administration testing and other assays that are notoriously
difficult to perform using mice.
6. Conclusions
As this brief review has demonstrated, the DID procedure has been extremely beneficial in
examining the central neurochemical pathways that modulate binge-like ethanol drinking.
This simple procedure reliably generates high levels of ethanol consumption and
corresponding high, pharmacologically relevant BECs that exceed the criteria of a binge [3].
Additionally, this procedure provides several benefits above other currently utilized models
of binge-like ethanol consumption, in that animals consistently and voluntarily consume
high concentrations of ethanol without the need of fluid or food restriction or sucrose fading
techniques. Using this technique, a great deal of information has been garnered about the
involvement of GABAergic, glutamatergic, dopaminergic, and opioidergic systems in
modulating binge-like ethanol consumption. Roles for the nicotinic, endocannabinoid, CRF,
NPY, melanocortin, and ghrelin systems have also been suggested. In addition to examining
the specific neurochemical systems outlined above, the flexible mouse DID model has also
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been used in a variety of other studies, beyond the scope of this review, including those that
model prenatal binge-like ethanol exposure [69] and that examine the effects of ethanol
dose-response self-administration patterns using cDNA [70].
Finally, research on binge-like ethanol consumption has suggested that different neural
mechanisms may underlie binge-like and non-binge-like ethanol intake. For example, in the
CRF studies mentioned above (see 4.6) CRF1R antagonism blunted binge-like ethanol
consumption, but did not affect moderate, non-binge like ethanol consumption [52, 53],
paralleling the observation that CRF receptor antagonists blunt excessive dependence-like
ethanol consumption but fail to alter low-level consumption in non-dependent animals [71,
72]. The similarities between models of excessive binge-like ethanol drinking and
dependence-like ethanol intake suggest that overlapping mechanisms may be present. Thus,
it is possible that excessive binge-like drinking in non-dependent animals may trigger
transient neurochemical alterations (e.g., increased CRF1R signaling) in critical pathways
analogous to what occurs after the development of dependence. These transient
neurochemical changes may motivate binge-like drinking as do permanent neurochemical
changes in motivating dependence-induced drinking. Increased CRF1R signaling stemming
from binge-like ethanol drinking may worsen and fail to “normalize” with repeated binge
episodes, ultimately contributing to the transition to dependence, consistent with the
allostasis model [73]. Clearly, much more work will be needed to verify this hypothesis, and
studies employing procedures that model binge ethanol drinking may help clarify this
important gap in the literature.
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Over the last several years, a large focus of pre-clinical research has been aimed at
the neurobiology of ethanol dependence.
A growing body of literature is emerging investigating the neurobiology of binge-
like ethanol drinking in non-dependent animals.
The present paper overviews recent findings on the neurobiology of binge-like
ethanol drinking in animals models.
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Table 1
Summary of DID Studies: Neurobiological Mechanisms of Binge-like Ethanol Consumption
System Examined Major Finding DID Procedure Details Study
Glutamate Acamprosate (i.p.) and MPEP (i.p) ↓ 20%
EtOH consumption
2-d procedure; 2-h (Acamprosate) and 4-h (MPEP)
EtOH access
[35]
GABAergic Ro15-4513 (i.p.; intra-VTA) ↓ 20% EtOH
consumption
7-d procedure; 2-h EtOH access [36]
Baclofen (i.p.) ↑, muscimol (i.p.) ↓ 20% EtOH
consumption
5-d procedure; 2-h EtOH access [37]
Baclofen (intra-VTA) ↑ 20% EtOH
consumption (intra-VTA)
16-d procedure; 2-h EtOH access [38]
Dopaminergic & opioidergic Naltrexone (i.p) and GBR 12909 (i.p) ↓ 20%
EtOH consumption
2-d procedure; 2-h EtOH access [41]
D2LR KO mice showed ↑ 20% EtOH
consumption compared to WT mice
4-d procedure; 2-h EtOH access days 1–3, 4-h EtOH
access day 4
[42]
Nicotinic Mecamylamine (i.p.), cytisine (i.p.), and
nicotine (i.p.) ↓ 20% EtOH consumption
2-d procedure; 2-h EtOH access [47]
Lobeline HCL (s.c.) ↓ 20% EtOH
consumption
2-d procedure; 4-h EtOH access [48]
Endocannabinoid WIN 55-313 (i.p.) dose-dependently
modulated 20% EtOH consumption; pVTA
administration altered the time course of
ethanol consumption
7-d procedure; 2-h EtOH access [31]
CRF CP-154, 526 (i.p.) ↓ binge-like 20% EtOH
consumption, but not low-level EtOH
consumption
4-d procedure; 4-h EtOH access days 1–4; 2-h EtOH
access days 1–3, 4-h EtOH access day 4
[52]
α-helical CRF9–41 (i.c.v.) and Ucn3 (i.c.v.) ↓
20% EtOH consumption
4-d procedure; 2-h EtOH access days 1–3, 4-h EtOH
access day 4
[53]
Ucn1 (intra lateral septum) ↓20% EtOH
consumption
3-d procedure; 2-h EtOH access [54]
CRF1 KO and CRF KO mice show ↓ binge-
like consumption of 20% EtOH relative to
WT mice
4-d procedure; 2-h EtOH access days 1–3, 4-h EtOH
access day 4
[55]
Melanocortin AgRP KO mice showed ↓ binge-like 20%
EtOH consumption relative to WT mice
4-d procedure; 2-h EtOH access days 1–3, 4-h EtOH
access day 4
[56]
NPY NPY (i.c.v.), Y1R agonist (i.c.v.), and Y2R
antagonist (i.c.v.) ↓ 20% EtOH consumption;
history of binge-like 20% EtOH consumption
altered NPY, Y1R, and Y2R
immunoreactivity in the CeA and ↑ NPY-
induced inhibition of GABAergic
transmission in slice preparations of CeA
4-d procedure; 2-h EtOH access days 1–3, 4-h
access day 4
[29]
Ghrelin Neither leptin (i.p.), ghrelin (i.p.), nor food
restriction altered 20% EtOH consumption
4-d procedure; 2-h EtOH access days 1–3, 4-h EtOH
access day 4
[30]
D-Lys-3-GHRP-6 (i.p.) ↓ 20% EtOH
consumption
7-d procedure; 2-hr EtOH access days 4–6, 4-hr
EtOH access day 7
[60]
(DID, drinking in the dark; ↓, decrease or attenuation; ↑, increase)
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